Indications for transcatheter mitral valve replacement based on mitral regurgitation-related research_West China Medical Journal

Authors：

WU Chan ,  LI Yan

Department of Cardiology, Tangdu Hospital, Airforce Medical University, Xi’an, Shaanxi 710032, P. R. China;

Corresponding author：

LI Yan, Email: profleeyan@163.com

Keywords：

Mitral regurgitation; transcatheter mitral valve replacement; indications

DOI：

10.7507/1002-0179.202408328

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Mitral regurgitation (MR) is the most common type of valvular heart disease. Mitral valve repair/replacement can improve the prognosis of patients with severe MR, but a large proportion of patients cannot tolerate surgical procedures due to comorbidities and surgical risks. Transcatheter mitral valve replacement (TMVR) is a kind of treatment for mitral valve disease in which an artificial valve is delivered to the mitral valve annulus through a catheter and released into place, with the advantages of no thorax opening, less trauma and high safety. Early clinical studies of TMVR have shown good results, but still face many challenges. Strict indications are effective measures to reduce surgical risks and postoperative complications. This article explores the relevant indications of TMVR by analyzing several studies at home and abroad.

1.	Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart, 2016, 102(1): 75-85.
2.	Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
3.	潘文志, 周达新, 葛均波. 中国二尖瓣反流患者人群数量的估测. 中国胸心血管外科临床杂志, 2021, 28(5): 495-498.
4.	Dufendach K, Aranda-Michel E, Sultan I, et al. Outcomes of mitral valve surgery for severe ischemic mitral regurgitation. J Card Surg, 2020, 35(2): 390-396.
5.	Zhuge RQ, Hou XP, Qi XL, et al. Clinical features and treatment options for mitral regurgitation in elderly inpatients. J Geriatr Cardiol, 2018, 15(6): 428-433.
6.	Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol, 2014, 63(2): 185-186.
7.	Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): 450-500.
8.	Debonnaire P, Heyning CMV, Haddad ME, et al. Left ventricular end-systolic dimension and outcome in patients with heart failure undergoing percutaneous mitraclip valve repair for secondary mitral regurgitation. Am J Cardiol, 2020, 126: 56-65.
9.	Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
10.	中国医师协会超声分会超声心动图专业委员会, 中国医师协会心血管内科医师分会结构性心脏病学组. 二尖瓣经导管缘对缘修复的超声心动图操作规范中国专家共识. 中国介入心脏病学杂志, 2022, 30(10): 721-733.
11.	潘文志, 李伟, 周达新, 等. 二尖瓣反流的新分型及相应经导管缘对缘修复手术策略中华心脏与心律电子杂志, 2024, 12(1): 10-13.
12.	Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve disease-current management and future challenges. Lancet, 2016, 387(10025): 1324-1334.
13.	中华医学会胸心血管外科分会瓣膜病外科学组. 功能性二尖瓣关闭不全外科治疗中国专家共识. 中华胸心血管外科杂志, 2022, 38(3): 156-163.
14.	Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. Eur Heart J, 2007, 28(11): 1358-1365.
15.	Taramasso M, Candreva A, Pozzoli A, et al. Current challenges in interventional mitral valve treatment. J Thorac Dis, 2015, 7(9): 1536-1542.
16.	Head SJ, van Leeuwen WJ, Van Mieghem NM, et al. Surgical or transcatheter mitral valve intervention: complex disease requires complex decisions. EuroIntervention, 2014, 9(10): 1133-1135.
17.	Xu H, Liu Q, Cao K, et al. Distribution, characteristics, and management of older patients with valvular heart disease in China: China-DVD Study. JACC Asia, 2022, 2(3): 354-365.
18.	Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2017, 135(25): e1159-e1195.
19.	Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, 379(24): 2307-2318.
20.	Asgar AW, Khairy P. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med, 2011, 365(1): 90.
21.	Smith R, Szerlip M, Lim S, et al. Six-month and one-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. J Am Coll Cardiol, 2020, 76(17): B3.
22.	Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol, 2015, 66(25): 2844-2854.
23.	Chiarito M, Pagnesi M, Martino EA, et al. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart, 2018, 104(4): 306-312.
24.	Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol, 2017, 70(19): 2315-2327.
25.	Suri RM, Clavel MA, Schaff HV, et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: long-term analysis of competing outcomes. J Am Coll Cardiol, 2016, 67(5): 488-498.
26.	Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
27.	Sorajja P, Gössl M, Babaliaros V, et al. Novel transcatheter mitral valve prosthesis for patients with severe mitral annular calcification. J Am Coll Cardiol, 2019, 74(11): 1431-1440.
28.	Alperi A, Granada JF, Bernier M, et al. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol, 2021, 77(24): 3058-3078.
29.	Fukui M, Sorajja P, Gössl M, et al. Left ventricular remodeling after transcatheter mitral valve replacement with tendyne: new insights from computed tomography. JACC Cardiovasc Interv, 2020, 13(17): 2038-2048.
30.	Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
31.	Del Val D, Ferreira-Neto AN, Wintzer-Wehekind J, et al. Early experience with transcatheter mitral valve replacement: a systematic review. J Am Heart Assoc, 2019, 8(17): e013332.
32.	Barbanti M, Piazza N, Mangiafico S, et al. Transcatheter mitral valve implantation using the highlife system. JACC Cardiovasc Interv, 2017, 10(16): 1662-1670.
33.	Schneider LM, Worthley S, Nickenig G, et al. 1-Year outcomes following transfemoral transseptal transcatheter mitral valve replacement: the highlife TSMVR feasibility study. JACC Cardiovasc Interv, 2023, 16(23): 2854-2865.
34.	Maisano F, Benetis R, Rumbinaite E, et al. 2-year follow-up after transseptal transcatheter mitral valve replacement with the cardiovalve. JACC Cardiovasc Interv, 2020, 13(17): e163-e164.
35.	Nunes Ferreira-Neto A, Dagenais F, Bernier M, et al. Transcatheter mitral valve replacement with a new supra-annular valve: first-in-human experience with the altavalve system. JACC Cardiovasc Interv, 2019, 12(2): 208-209.
36.	Goel SS, Zuck V, Christy J, et al. Transcatheter mitral valve therapy with novel supra-annular altavalve: first experience in the United States. JACC Case Rep, 2019, 1(5): 761-764.
37.	Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. J Am Coll Cardiol, 2019, 73(11): 1239-1246.
38.	Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv, 2020, 13(20): 2418-2426.
39.	Alperi A, Dagenais F, Del Val D, Bernier M, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv, 2020, 13(20): 2427-2437.
40.	Modine T, Vahl TP, Khalique OK, et al. First-in-human implant of the cephea transseptal mitral valve replacement system. Circ Cardiovasc Interv, 2019, 12(9): e008003.
41.	中国医师协会心血管内科医师分会结构性心脏病专业委员会. 中国经导管主动脉瓣置换术临床路径专家共识(2021 版). 中国介入心脏病学杂志, 2022, 30(1): 7-16.

1. Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart, 2016, 102(1): 75-85.
2. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
3. 潘文志, 周达新, 葛均波. 中国二尖瓣反流患者人群数量的估测. 中国胸心血管外科临床杂志, 2021, 28(5): 495-498.
4. Dufendach K, Aranda-Michel E, Sultan I, et al. Outcomes of mitral valve surgery for severe ischemic mitral regurgitation. J Card Surg, 2020, 35(2): 390-396.
5. Zhuge RQ, Hou XP, Qi XL, et al. Clinical features and treatment options for mitral regurgitation in elderly inpatients. J Geriatr Cardiol, 2018, 15(6): 428-433.
6. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol, 2014, 63(2): 185-186.
7. Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): 450-500.
8. Debonnaire P, Heyning CMV, Haddad ME, et al. Left ventricular end-systolic dimension and outcome in patients with heart failure undergoing percutaneous mitraclip valve repair for secondary mitral regurgitation. Am J Cardiol, 2020, 126: 56-65.
9. Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
10. 中国医师协会超声分会超声心动图专业委员会, 中国医师协会心血管内科医师分会结构性心脏病学组. 二尖瓣经导管缘对缘修复的超声心动图操作规范中国专家共识. 中国介入心脏病学杂志, 2022, 30(10): 721-733.
11. 潘文志, 李伟, 周达新, 等. 二尖瓣反流的新分型及相应经导管缘对缘修复手术策略中华心脏与心律电子杂志, 2024, 12(1): 10-13.
12. Nishimura RA, Vahanian A, Eleid MF, et al. Mitral valve disease-current management and future challenges. Lancet, 2016, 387(10025): 1324-1334.
13. 中华医学会胸心血管外科分会瓣膜病外科学组. 功能性二尖瓣关闭不全外科治疗中国专家共识. 中华胸心血管外科杂志, 2022, 38(3): 156-163.
14. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. Eur Heart J, 2007, 28(11): 1358-1365.
15. Taramasso M, Candreva A, Pozzoli A, et al. Current challenges in interventional mitral valve treatment. J Thorac Dis, 2015, 7(9): 1536-1542.
16. Head SJ, van Leeuwen WJ, Van Mieghem NM, et al. Surgical or transcatheter mitral valve intervention: complex disease requires complex decisions. EuroIntervention, 2014, 9(10): 1133-1135.
17. Xu H, Liu Q, Cao K, et al. Distribution, characteristics, and management of older patients with valvular heart disease in China: China-DVD Study. JACC Asia, 2022, 2(3): 354-365.
18. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2017, 135(25): e1159-e1195.
19. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, 379(24): 2307-2318.
20. Asgar AW, Khairy P. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med, 2011, 365(1): 90.
21. Smith R, Szerlip M, Lim S, et al. Six-month and one-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. J Am Coll Cardiol, 2020, 76(17): B3.
22. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol, 2015, 66(25): 2844-2854.
23. Chiarito M, Pagnesi M, Martino EA, et al. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart, 2018, 104(4): 306-312.
24. Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol, 2017, 70(19): 2315-2327.
25. Suri RM, Clavel MA, Schaff HV, et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: long-term analysis of competing outcomes. J Am Coll Cardiol, 2016, 67(5): 488-498.
26. Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
27. Sorajja P, Gössl M, Babaliaros V, et al. Novel transcatheter mitral valve prosthesis for patients with severe mitral annular calcification. J Am Coll Cardiol, 2019, 74(11): 1431-1440.
28. Alperi A, Granada JF, Bernier M, et al. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol, 2021, 77(24): 3058-3078.
29. Fukui M, Sorajja P, Gössl M, et al. Left ventricular remodeling after transcatheter mitral valve replacement with tendyne: new insights from computed tomography. JACC Cardiovasc Interv, 2020, 13(17): 2038-2048.
30. Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
31. Del Val D, Ferreira-Neto AN, Wintzer-Wehekind J, et al. Early experience with transcatheter mitral valve replacement: a systematic review. J Am Heart Assoc, 2019, 8(17): e013332.
32. Barbanti M, Piazza N, Mangiafico S, et al. Transcatheter mitral valve implantation using the highlife system. JACC Cardiovasc Interv, 2017, 10(16): 1662-1670.
33. Schneider LM, Worthley S, Nickenig G, et al. 1-Year outcomes following transfemoral transseptal transcatheter mitral valve replacement: the highlife TSMVR feasibility study. JACC Cardiovasc Interv, 2023, 16(23): 2854-2865.
34. Maisano F, Benetis R, Rumbinaite E, et al. 2-year follow-up after transseptal transcatheter mitral valve replacement with the cardiovalve. JACC Cardiovasc Interv, 2020, 13(17): e163-e164.
35. Nunes Ferreira-Neto A, Dagenais F, Bernier M, et al. Transcatheter mitral valve replacement with a new supra-annular valve: first-in-human experience with the altavalve system. JACC Cardiovasc Interv, 2019, 12(2): 208-209.
36. Goel SS, Zuck V, Christy J, et al. Transcatheter mitral valve therapy with novel supra-annular altavalve: first experience in the United States. JACC Case Rep, 2019, 1(5): 761-764.
37. Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. J Am Coll Cardiol, 2019, 73(11): 1239-1246.
38. Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv, 2020, 13(20): 2418-2426.
39. Alperi A, Dagenais F, Del Val D, Bernier M, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv, 2020, 13(20): 2427-2437.
40. Modine T, Vahl TP, Khalique OK, et al. First-in-human implant of the cephea transseptal mitral valve replacement system. Circ Cardiovasc Interv, 2019, 12(9): e008003.
41. 中国医师协会心血管内科医师分会结构性心脏病专业委员会. 中国经导管主动脉瓣置换术临床路径专家共识(2021 版). 中国介入心脏病学杂志, 2022, 30(1): 7-16.

West China Medical Journal

Latest ArticlesIndications for transcatheter mitral valve replacement based on mitral regurgitation-related research

Abstract Full text Figures/Tables Video References Cited by

Format

Content